Salarius Pharmaceuticals to Report Second Quarter 2020 Financial Results

Rhea-AI Summary

Salarius Pharmaceuticals (SLRX) announced a conference call on August 12, 2020, at 4:30 p.m. ET, to present its Q2 2020 corporate and financial results. The company is focused on treating cancers linked to dysregulated gene expression, with its lead candidate, seclidemstat, in Phase 1/2 trials, specifically for Ewing sarcoma.

Salarius has received several designations from the FDA, including Fast Track and Orphan Drug Designations. The company also secured financial support for its clinical programs, including an $18.7 million award from CPRIT.

Positive

• Seclidemstat is in Phase 1/2 clinical trials for Ewing sarcoma.
• Received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation from FDA.
• $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas.

Negative

• None.

HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced that the Company will host a conference call and live audio webcast on Wednesday, August 12, 2020, at 4:30 p.m. ET, to discuss its corporate and financial results for the second quarter 2020.

Conference Call Information:

Interested participants and investors may access the conference call by dialing either:

• (833) 423-0481 (U.S.)
• (918) 922-2375 (international)
• Conference ID: 9367616

An audio webcast will be accessible via the Investors Events & Presentations section of the Company’s website, http://investors.salariuspharma.com/. An archive of the webcast will remain available for 90 days beginning at approximately 5:30 p.m. ET, on Wednesday, August 12, 2020.

About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting cancers caused by dysregulated gene expression and is developing treatments for patients that need them the most. Epigenetics refers to the regulatory system that affects gene expression. Salarius’ lead candidate, seclidemstat, is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com.

Contact

Investor Relations
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA/Miriam Miller
(212) 375-2664 / 2694
mmcenroe@tiberend.com
mmiller@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Johanna Bennett
(212) 375-2686
jbennett@tiberend.com

FAQ

When is the Salarius Pharmaceuticals conference call for Q2 2020?

Salarius Pharmaceuticals will host its Q2 2020 conference call on August 12, 2020, at 4:30 p.m. ET.

What is the focus of Salarius Pharmaceuticals?

Salarius Pharmaceuticals focuses on developing treatments for cancers caused by dysregulated gene expression.

What designations has Salarius Pharmaceuticals received for seclidemstat?

Seclidemstat has received Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA.

What support has Salarius Pharmaceuticals secured for its clinical programs?

Salarius Pharmaceuticals secured an $18.7 million Product Development Award from CPRIT to advance its clinical programs.